Pal-AHK (Palmitoyl Ala-His-Lys): Lipidated Tripeptide Design, AHK-Cu Hair-Follicle Evidence, and the Limits of Structure-to-Function Extrapolation

1. Molecular Identity and Naming Discipline 1.1 What “Pal-AHK” Conventionally Describes The name Pal-AHK conventionally denotes a molecule composed of the AHK sequence—alanine, histidine, and lysine—bearing a palmitoyl group at its N-terminus. Palmitoyl refers to a 16-carbon saturated fatty-acid-derived chain. Attaching this hydrophobic chain yields a lipopeptide that is chemically distinct from the unmodified, hydrophilic AHK tripeptide. It should be distinguished from AHK-Cu, in which the histidine-containing peptide coordinates copper(II), and from Pal-GHK (Palmitoyl Tripeptide-1), which has the different Gly-His-Lys sequence. The practical consequence is straightforward: an informal peptide name is not a complete characterization. A research material labeled Pal-AHK should be verified by a certificate of analysis, molecular mass, analytical purity, full structure, counterion or salt form, and a statement of whether any metal complex is present. Without that documentation, claims about “Pal-AHK” may inadvertently combine evidence for different materials under one label. 1.2 AHK-Cu versus Pal-AHK | Feature | Pal-AHK | AHK-Cu | Why the Distinction Matters | | --- | --- | --- | --- | | Core scaffold | Proposed Ala-His-Lys tripeptide with N-terminal C16 palmitoyl chain. | Ala-His-Lys tripeptide coordinated to Cu²⁺ [1]. | Lipidation and metal coordination are different chemical modifications. | | Direct peer-reviewed study located? | No Pal-AHK-specific primary paper located in the reviewed source set. | Yes: hair-follicle and dermal-papilla experiments [1]. | Evidence for AHK-Cu cannot validate Pal-AHK. | | Chemistry expected to change | Higher hydrophobicity and formulation/partitioning behavior. | Copper coordination chemistry and redox/metal availability. | Different exposure, stability, aggregation, and targets are plausible. | | Human clinical evidence | No Pal-AHK human trial identified. | No clinical hair-regrowth trial established by the cited 2007 study. | Ex-vivo activity is not clinical efficacy. | 2. What N-Terminal Palmitoylation Can—and Cannot—Establish 2.1 Lipopeptide Design Logic N-terminal lipidation is a common strategy in peptide design because it can alter peptide–vehicle interactions, adsorption to lipid-rich surfaces, aggregation, solubility, proteolytic accessibility, and local partitioning. In cosmetic-peptide development, a palmitoyl group is often intended to support formulation compatibility and localization within the stratum-corneum environment. These are design rationales rather than product-specific proof. Palmitoylation can also introduce formulation challenges, including altered dispersion, adsorption to packaging, and concentration-dependent aggregation. 2.2 What Remains Unknown for Pal-AHK No Pal-AHK-specific permeability, stability, bioavailability, receptor-binding, copper-binding, dermal-papilla, fibroblast, collagen, or human clinical dataset was identified in the reviewed peer-reviewed sources. Therefore, it is not valid to state that Pal-AHK penetrates skin more effectively, is more stable, stimulates collagen, signals through a particular receptor, or promotes hair growth. Those are testable hypotheses, not established properties. Direct evidence would require chromatographic stability studies, skin-distribution measurements, cell-assay dose–response work, target-engagement experiments, and blinded human studies if any clinical claim were considered. “In the present study, the effects of L-alanyl-L-histidyl-L-lysine-Cu²⁺ (AHK-Cu) on human hair growth ex vivo and cultured dermal papilla cells were evaluated.” — Pyo et al., Archives of Pharmacal Research, 2007 [1] 3. Direct Related Evidence: AHK-Cu in Hair-Follicle Models 3.1 Human Follicles Ex Vivo and Dermal-Papilla Cells In Vitro Pyo and colleagues evaluated AHK-Cu at 10⁻¹² to 10⁻⁹ M in cultured human hair follicles and dermal-papilla cells. They reported increased human hair-follicle elongation ex vivo and increased dermal-papilla-cell proliferation in vitro [1]. Dermal papilla cells are specialized mesenchymal cells important to hair-follicle signaling, making the model relevant for basic hair-biology screening. Still, ex-vivo follicle elongation and cultured-cell proliferation are intermediate research endpoints. They do not establish efficacy in androgenetic alopecia, durability of effect, optimal delivery, comparative effectiveness, or safety in people. 3.2 Apoptosis-Related Measurements At 10⁻⁹ M, AHK-Cu increased the Bcl-2/Bax ratio and reduced cleaved caspase-3 and PARP in dermal-papilla cells [1]. The reported reduction in apoptotic cells by flow cytometry was not statistically significant. That nuance matters: the study supports a hypothesis of altered survival-related signaling but does not prove that apoptosis suppression is the primary mechanism of follicle elongation. It also does not identify whether copper coordination, the AHK sequence, or their combined physicochemical properties were necessary for

For research use only. Not for human consumption.